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Abstract
Background: The WNT1-inducible signaling pathway protein 3 (WISP3), which belongs to the CCN (cysteine-rich protein 61,
connective tissue growth factor, nephroblastoma overexpressed) family, is a secreted cysteine-rich matricellular protein that
is involved in chondrogenesis, osteogenesis and tumorigenesis. WISP3 gene mutations are associated with progressive
pseudorheumatoid dysplasia (PPD, OMIM208230), an autosomal recessive genetic disease that is characterized by the
swelling of multiple joints and disproportionate dwarfism.
Methodology/Principal Findings: Four PPD patients from two unrelated Chinese families were recruited for this study. The
clinical diagnosis was confirmed by medical history, physical examinations, laboratory results and radiological abnormalities.
WISP3 mutations were detected by direct DNA sequence analysis. In total, four different mutations were identified, which
consisted of two missense mutations, one deletion and one insertion that spanned exons 3, 5 and 6 of the WISP3 gene. One
of the missense mutations (c.342T.G/p.C114W) and a seven-base pair frameshift deletion (c.716_722del/p.E239fs*16) were
novel. The other missense mutation (c.1000T.C/p. S334P) and the insertion mutation (c.866_867insA/p.Q289fs*31) had
previously been identified in Chinese patients. All four cases had a compound heterozygous status, and their parents were
heterozygous carriers of these mutations.
Conclusions/Significance: The results of our study expand the spectrum of WISP3 mutations that are associated with PPD
and further elucidate the function of WISP3.
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Introduction
Progressive pseudorheumatoid dysplasia (PPD,
OMIM208230), also referred to as spondyloepiphyseal dysplasia
tarda with progressive arthropathy (SEDT-PA) or progressive
pseudorheumatoid arthritis of childhood (PPAC), is an autosomal
recessive genetic disease. The disorder manifests prominently in
the skeletal system and presents with a disproportionately short
stature, i.e., a short neck and trunk, and progressive swelling and
stiffness in multiple joints. The PPD population incidence, which
is extremely low, is estimated to be one person per million in the
UK [1]. In fact, most PPD cases may remain undiagnosed
because of the similar skeletal abnormalities shared with other
arthropathies, spondyloepiphyseal dysplasia and glycogen storage
diseases. Therefore, an accurate PPD population incidence is
unknown. A comprehensive understanding of the disease should
be improved, and genetic diagnosis for this type of disease is
imperative
WISP3, the gene that is effected in PPD [2], is located on
chromosome 6q22 and consists of 6 exons that span approximately
15 kb. The coding region, which is 1065 bp in size, is
encompassed by exons 2–6 and yields a 354-amino acid protein
that is referred to as WISP3 and has additional alternatively
spliced exons described in the database. WISP3 (WNT1-inducible
signaling pathway protein 3), also named CCN6, belongs to the
CCN (cysteine-rich protein 61, connective tissue growth factor,
nephroblastoma overexpressed) family of matricellular proteins
and mediates developmental functions. This family of proteins,
which is most likely involved in the control of cell differentiation
and proliferation, participates in angiogenesis, chondrogenesis,
and osteogenesis [3]. The extensive biological functions of WISP3
(CCN6), especially in skeletal development and cell survival and
apoptosis, are of great academic interest. The fact that WISP3
mutations are linked to PPD has confirmed the protein’s essential
role in chondrogenesis and osteogenesis.
The first identification of this causative gene responsible for
PPD occurred in 1999, and new pathogenic mutations have been
found in recent years. However, the role of WISP3 in chondrocyte
proliferation and differentiation and the mechanism by which
these mutations cause PPD have not been established. The
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38643characterization of such mutations will help to elucidate the
important functional domains of WISP3. Therefore, we performed




Family 1. Family 1 consists of 2 brothers who were affected
with PPD with different degrees of severity. These brothers were
born from non-consanguineous parents. Both of the parents were
of normal height and presented no evidence of arthritis.
The proband (II 2 in family 1), a 5-year-old boy, was referred to
our clinic in October 2005. His parents communicated the boy’s
complaint of multiple joint swelling, which began at the age of 4.
The swelling first affected the proximal interphalangeal joints, and
subsequently, the metacarpophalangeal and distal interphalangeal
joints. During the initial examination, the boy presented with
a minimal fusiform swelling of the metacarpophalangeal and
interphalangeal joints and a slight limitation in the extension of his
fingers, and his height was in the 10th–25th percentile for his age.
He was re-evaluated by us at the age of 10 after developing
bilateral swelling and stiffness in his elbow, knee and ankle joints.
At this time, his height was below the 3
rd percentile for his age
(shown in Figures 1A and B). The boy did not complain of pain in
his hands, legs or back. X-ray images (at 5 years old) revealed
a platyspondyly and ovoid anterior end-plate of the vertebral
bodies on the thoracolumbar spine, a widened elbow and tibial
metaphysis. An enlargement of epiphysis did not exist, and the
pelvis appeared normal (shown in Figures 1C–F).
The patient II 1 in family 1 came to our clinic at the age of 20,
with the same age of disease onset but more severe symptoms
compared with the proband in family 1. He presented with joint
deformities, a walking disability and secondary myatrophy at the
age of 15. His radiographic images (at 15 years old) demonstrated
flattening and anterior beaking of the thoracolumbar spine with an
increased anteroposterior diameter of the vertebral bodies,
irregular upper and lower end-plates, narrow disc spaces and
short pedicles. Enlargements of the interphalangeal and genual
epiphyses and a deformed pelvis with bilateral femoral neck
fractures and enlarged capital femoral epiphyses were observed
(shown in Figures 2G–J).
Family 2. The proband was born from non-consanguineous
parents with an affected little brother. Both parents were
unaffected.
The proband (II 1 in family 2) was thought to be normal for his
first few years of life. At the age of 5, swelling and then stiffness of
the interphalangeal and metacarpophalangeal joints emerged. The
knees, elbows and hips were all affected at the age of 12. At 14
years of age, the boy presented at the clinic with short-trunk
disproportionate dwarfism, scoliosis and a waddling gait. X-ray
images showed flattening vertebrae on the cervical, thoracic and
lumbar spine with anterior beaking, an increased anteroposterior
diameter of the vertebral bodies, enlargement of the interphalan-
geal, metacarpal, elbow, genual, ankle and femoral epiphyses with
narrow joint spaces and irregular articular surfaces. The skull was
normal (Figures 3A–F).
The patient II 2 in family 2 was examined at the age of 4 as part
of the family study for his 14-year-old brother (The proband in
family 2). Swelling of the interphalangeal articulations was found
to be his first clinical abnormality. At his second clinic visit at the
age of 6, subtle symptoms consisting of swelling of interphalangeal,
metacarpophalangeal and knee joints without stiffness observed
(Figures 4G and H). The radiological findings were an increased
anteroposterior diameter of the vertebral bodies, irregular
vertebral end-plates and a slight enlargement of the metaphyses
Figure 1. The photographs and X-ray images of the proband in family 1. (A&B) Short-trunk disproportionate dwarfism and enlargement of
the elbow and genual joints; (C) platyspondyly and ovoid anterior end-plate of vertebral bodies; (D) widened tibial metaphysis; (E) widened cubital
metaphysis; (F) a normal pelvis at 5 years of age.
doi:10.1371/journal.pone.0038643.g001
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38643Figure 2. The X-ray images of patient II 1 in family 1. (G) Platyspondyly of the lumbar spine: the vertebral bodies are wedged anteriorly, and
there are narrow disc spaces, irregular vertebral end-plates and short pedicles; (H) enlargement of the epiphyseal and metaphyseal portions of the
metacarpals and phalanges; (I) bilateral femoral neck fractures and enlargement of the capital femoral epiphyses; (J) an enlargement of genual
epiphyses.
doi:10.1371/journal.pone.0038643.g002
Figure 3. The X-ray images of patient II 1 in family 2. (A) Flattened vertebrae on the cervical spine and normal skull; (B) flattened vertebrae on
the thoracic and lumbar spine with anterior beaking and an increased anteroposterior diameter of the vertebral bodies; (C) enlargement of the
interphalangeal, metacarpal and metacarpophalangeal epiphyses; (D) narrow joint spaces and irregular articular surfaces of hip joints with short
femoral necks; (E) slight enlargement of elbow epiphyses and metaphyses; (F) flattened talus with narrow joint spaces.
doi:10.1371/journal.pone.0038643.g003
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(Figures 4I–K). The routine blood test results (i.e., erythrocyte
sedimentation rate, C-reactive protein, rheumatoid factor, serum
calcium levels, serum phosphorus levels, alkaline phosphatase,
parathyroid hormone, vitamin D status and insulin-like growth
factor 1) of these four patients were within the normal range.
Mutation identification
Family 1. The same compound heterozygous WISP3 muta-
tion occurred in patients II 1 and II 2 as follows (Figure 5): 1.
a missense mutation c.1000T.C in exon 6, which was the
transition of a single nucleotide TRC that caused the amino acid
serine (TCT) in codon 334 to change to proline (CCT); this
mutation was also detected in the heterozygous state in their
father; and 2. a frameshift mutation c.866_867insA in exon 6,
which was an insertion of a nucleotide in codon 289 (glutamine) of
the WISP3 gene that caused a frame shift of the coding region; this
mutation was also detected in the heterozygous state in their
mother.
Family 2. The same compound heterozygous mutation of
WISP3 occurred in patient II 1 and II 2 as follows (Figure 5): 1.
a missense mutation c.342T.G in exon 3, which was the
transition of a single nucleotide TRG that caused the amino acid
cystine (TGT) in codon 114 to change to tryptophan (TGG); this
mutation was also detected in the heterozygous state in their
mother; and 2. a frameshift mutation c.716_722delAAATGAG in
exon 5, which was a 7-nucleotide deletion from codon 239
(glutamic acid) of the WISP3 gene that caused a frame shift of the
coding region; this mutation was also detected in the heterozygous
state in their father.
Discussion
Progressive pseudorheumatoid dysplasia (PPD) is an autosomal
recessive genetic disease that is characterized by stiffness and
enlargement of limb joints, a short stature and gait instability. The
radiographic characteristics that distinguish PPD from other
arthropathies include widened epiphyses and vertebral flattening.
A normal life expectancy is estimated, whereas joint contractures,
fractures and spinal stenosis are major prognostic factors in PPD.
In our study, all four patients experienced almost the same clinical
course as follows (Table 1): onset at the age of 4 or 5, progressive
joint swelling (e.g., in hands, elbows, hips, knees and ankles), a short
stature and a mode of inheritance consistent with autosomal
recessive transmission. The X-ray images displayed mainly
platyspondyly with irregularly shaped vertebrae, widened epiph-
yses and metaphyses of the long bones, narrow joint spaces and
osteopenia. Notably, the present cases have a similar phenotypic
expression and a different degree of severity within the same
family. The older brother exhibits a more severe phenotype with
a more serious involvement of height growth retardation and
multiple joint swelling and stiffness, whereas his younger brother
presents with a height that is slightly below the normal range and
no early symptoms of degenerative osteoarthrosis. Moreover, at
the radiological level, a different degree of severity was evident by
observing the flattened vertebral bodies that were more prominent
in the older brother. During several years of follow-up visits, we
observed that the PPD symptoms worsened with age. Therefore,
follow-up periods should proceed to acquire progression and
prognosis data.
The gene that is mutated in PPD is located on chromosome
6q22 and consists of 5 coding exons, which are translated to an
354 amino acid protein that is referred to as WNT1-inducible
signaling protein 3 (WISP3). To date, 23 different WISP3
mutations have been detected globally in more than 30 PPD
Figure 4. The photographs and X-ray images of patient II 2 in family 2. (G) The hands display interphalangeal joint swelling; (H) a swollen
knee; (I) slight enlargement of the metacarpophalangeal epiphyses; (J) slight enlargement of the femoral and tibial epiphyses; (K) an increased
anteroposterior diameter of the vertebral bodies and irregular vertebral end-plates.
doi:10.1371/journal.pone.0038643.g004
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is presented (Table 2). We have identified two novel mutations,
c.342T.G/p.Cys114Trp and c.716_722delAAATGAG/
p.Glu239fs*16, and two recurrent mutations, c.1000T.C/
p.Ser334Pro and c.866_867ins A/p.Gln289fs*31, in four PPD
patients from two unrelated Chinese families.
The novel missense mutation c.342T.G causes the amino acid
cystine (TGT) to change to tryptophan (TGG) at codon 114. This
sequence variation was not present in any of the control samples,
which indicates that this variation is not a single nucleotide
polymorphism (SNP). The p.114cystine is highly evolutionarily
conserved among variant species according to database analysis.
Yue et al. [4] have reported a homozygous missense mutation,
p.Cys114Tyr, which causes the substitution of cystine by tyrosine
at the same position in the amino acid sequence. A patient
carrying this homozygous mutation has severe PPD symptoms,
which indicates that the amino acid residue cystine at codon 114 is
critical for WISP3 protein function. C114W and C114Y are in the
Figure 5. The pedigrees and automated sequencing traces of the WISP3 gene mutations in the two families in our study.
doi:10.1371/journal.pone.0038643.g005
Table 1. General characteristics of 4 PPD patients in two families
II1 in family 1 II2 in family 1 II1 in family 2 II2 in family 2
Age of onset 44 5 4
Age at examination 20 10 14 6
Onset body part interphalangeal interphalangeal interphalangeal interphalangeal
Swelling joints + + + +
Painful joints 2 2 2 2
LFE of Knee + + + 2
LFE of Hip + 2 + 2
LFE of Elbow + + + 2
Short stature + + + 2
Scoliosis 2 2 + 2
Waddling gait + + + 2
Disability + 2 2 2
Muscle wasting + 2 2 2
Widened epiphyses + + + +
Platyspondyly + 2 + 2
‘‘+’’: positive manifestations; ‘‘2’’: normal. ‘‘LFE’’: Limited flexion and extension. The data of age are showed in years.
doi:10.1371/journal.pone.0038643.t001
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WISP3 [5]. Another missense mutation, C78R (the substitution of
cystine by arginine at codon 78), is in the same domain and causes
a reduced activity that inhibits BMP and Wnt signaling during
cartilage development [6]. The mutations C114W and C114Y
have recently been identified and may cause a similar loss of
function.
The other novel mutation, c.716_722delAAATGAG/
p.Glu239fs*16, was identified in patients II 1 and II 2 in family
2 and in the heterozygous state in their father. It has been
predicted that this mutation will cause a translational substitution
from codon 239, and the truncated protein has a loss of 99 amino
acids. This loss includes the entire length of exon 6, which encodes
a ‘carboxyterminal cystine knots’ domain that may participate in
dimerization and receptor binding [5]. Previous literature
indicates that mutations in exon 6 have frequently been identified
in PPD patients. These findings indicate that the frameshift
mutation that includes the deletion of exon 6 is a pathogenic
mutation. Additionally, the absence of DNA sequence abnormal-
ities in 100 alleles from 50 unrelated normal individuals validates
that these abnormalities are mutations and unlikely to be
polymorphisms.
We also identified the following two recurrent mutations:
a missense mutation (c.1000T.C/p.Ser334Pro) and a frameshift
mutation (c.866_867ins A/p.Gln289fs*31); these mutations have
previously been reported to be of Chinese origin [7,8]. Liao et al.
have predicted that the C-terminal peptide is located in the
opposite direction in the Ser334Pro mutant CCN6 protein with
another c.840delT in the compound heterozygous mutation,
which changes the 3D-conformational structure of the mutant
protein, and therefore concluded that the coexistence of
a c.1000T.C substitution is necessary for the clinical onset of
PPD [9]. Ye et al. have reported an affected Chinese individual
with a homozygous c.866_867insA mutation who displayed the
majority of the same symptoms as our patients [8]. This
mutation, which results in a truncated protein after a 34-amino
acid deletion, may change the entire protein structure and
function.
In 1999, WISP3 was found to be the causative gene for PPD
following linkage analysis [10]. In addition to our novel findings,
21 other mutations (i.e., three nonsense mutations, seven missense
mutations, eight deletion mutations, three insertion mutations and
two splice mutations) were identified in the WISP3 gene of these
PPD patients (Table 2). Significant variability exists in the WISP3
mutations that span the coding exons, and C52X, the recurrent
mutation, might be a hot-spot mutation that is distributed among
different ethnic populations in the Middle East and Europe.
Within the Chinese population, different forms of the WISP3 gene
mutation may exist. First, three recurrent mutations (i.e.,
c.624insA, c.866insA and c.1000T.C) have a Chinese origin.
The presence of the same aberration in different pedigrees could
imply a founder effect, and a haplotype analysis could confirm this.
Testing for these specific mutations in suspected PPD cases could
provide a rapid and definitive diagnosis. Second, approximately
Table 2. Summary of all currently known WISP3 gene mutations in PPD
No. Exon/intron Nucleotide change Amino acid change Origin References
1 intron2 g.IVS2+2insT splice Jordan [2]
2 exon2 c.43delGC A15fsX30 American [2]
3 exon2 c.136C.T G46X China [4]
4 exon2 c.156C.A C52X Turkey,
Lebanon,Syria,Italy,France
[2],[11], [12]
5 exon3 c.232T.C C78R France [2]
6 exon3 c.246delA P82fsX104 Saudi Arabia,Jordan [2]
7 exon3 c.341 G.A C114Y China [4]
8 exon3 c.342T.G C114W China This study
9 exon4 c.434G.A C145Y Italy [2]
10 exon4 c.535_536delTG or c.536_537delGT C179fsX Syria [12]
11 exon4 c.589G.C A197fsX4 Syria [12]
12 intron4 c.589+2T.C splice China [13]
13 exon5 c.624insA L208fsX22 China [8] [13]
14 exon5 c.716_722delAAATGAG E239fsX16 China This study
15 exon5 c.729_735delGAGAAAA M243fsX15 China [8]
16 exon5 c.739_740delTG C247fsX30 German [14]
17 exon5 c.840delT F280fsX32 China [7]
18 exon6 c.863insAC T288fsX25 American [2]
19 exon6 c.866insA Q289fsX31 China This study; [8]
20 exon6 c.866delAG Q289fsX12 Iran [2]
21 exon6 c.993G.A W331X Italy [2]
22 exon6 c.1000T.C S334P China This study; [7]
23 exon6 c.1013A.T Q338L Japan [6]
*Nucleotide numbers refer to genomic DNA and are numbered from the transcription start site. Amino acid replacement mutations are indicated according to codon
number; The reference sequence is available on the NCBI (GenBank accession number: NM_003880.3).
doi:10.1371/journal.pone.0038643.t002
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heterozygous carriers are found in the patients’ families, which
most likely suggests a higher PPD incidence in China. Regretfully,
not many cases have been reported, and the exact prevalence data
in China are unknown. Overall, a comprehensive understanding
of the disease would prevent unnecessary examinations and
treatments, and genetic counseling is necessary for all of the
members of the affected families to reduce the disease incidence in
China.
Although many WISP3 mutations exist, the PPD phenotypes in
our case study and those described by the literature were in
accordance with each other. We could hardly conclude that non-
sense or frameshift mutations are generally more severe than
missense mutations. However, our work raises several notable
points as follows: 1. no association between the order of the
mutations from 59 to 39 along the gene and a decrease in clinical
severity was apparent; 2. PPD patient symptoms were more severe
with advancing age; and 3. in contrast with previously reported
cases, arthralgia was not clearly observed in these two families,
excluding the hip pain observed in the advanced stage of the
disease.
In conclusion, our study of Chinese families with PPD reports
the detection of two novel and two recurrent WISP3 mutations,
which have not been identified in any other ethnic groups. Our
results, taken in the context of prior studies of WISP3 gene
analyses, confirm the notion that WISP3 mutation variability is
responsible for PPD and extend the spectrum of WISP3 gene
defects that cause PPD.
Materials and Methods
Ethics Statement
The study protocol was approved by the Medical Ethics
Committee of the Peking Union Medical College Hospital.
Written informed consent forms were obtained from the patients,
their parents and healthy controls. All clinical investigation was
conducted according to the principles expressed in the Declaration
of Helsinki. The patients in this manuscript gave written informed
consent to publish their case details.
Patients
Four affected individuals with PPD were enrolled and
designated as patients II 1 and II 2 in family 1, and II 1 and II
2 in family 2. The PPD diagnosis was determined by medical
history, physical examination and radiological abnormalities. After
obtaining informed consent, venous blood samples were obtained
from the four PPD patients, their parents and fifty controls. All of
the members of the two PPD families were of Chinese origin.
DNA sequence analysis of the WISP3 gene
Leukocytic DNA was prepared using a QIAGEN DNA mini
kit (Qiagen, Hilden, Germany). The DNA sequence abnormal-
ities of the WISP3 gene were initially detected in each of the four
PPD patients by the use of five PCR primer pairs (Table 3) that
were specific for coding exons 2 to 6 and exon-intron
boundaries. The PCR products were gel purified, and the
DNA sequences were determined by Taq polymerase cycle
sequencing and a semiautomated detection system (ABI 373XL
sequencer; Applied Biosystems, Foster City, CA). The DNA
sequence abnormalities, which were identified by comparison to
the reference sequence (GenBank accession number:
NM_003880.3), were confirmed and demonstrated to cosegre-
gate with the disorder and were absent in the DNA that was
obtained from 50 unrelated normal individuals (25 males and 25
females).
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